Literature DB >> 22587628

Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype.

Hans Ivar Hanevik1, Hilde Tveitan Hilmarsen, Camilla Furu Skjelbred, Tom Tanbo, Jarl A Kahn.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is a serious complication following controlled ovarian hyperstimulation (COH) for in vitro fertilization. OHSS has a range of clinical features from mild abdominal distention to severe thromboembolic events. Several clinical manifestations of OHSS such as ascites and hemoconcentration can be attributed to increased vascular permeability. Vascular endothelial growth factor (VEGF) and its receptor VEGFR2 have been identified as an important signaling system in mediating this increase. There is considerable genetic variation in the VEGF/R2 signaling system. We present the first study to examine if single nucleotide polymorphisms (SNPs) in the genes encoding the VEGF/R2 signaling system are associated with OHSS following COH. Blood samples from 53 OHSS patients and 100 controls were analyzed for six SNPs of interest. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated by a multivariate logistic regression model. We found an association between the VEGF +405cc genotype and OHSS (OR 3.4, 95% CI 1.01-11.7). This finding requires confirmation from other patient populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22587628     DOI: 10.3109/09513590.2012.683056

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

Review 1.  Polymorphisms of vascular endothelial growth factor and recurrent implantation failure: a systematic review and meta-analysis.

Authors:  Hong Zeng; Lian Hu; Hebin Xie; Wenmin Ma; Song Quan
Journal:  Arch Gynecol Obstet       Date:  2021-04-23       Impact factor: 2.344

2.  The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI.

Authors:  Radia Boudjenah; Denise Molina-Gomes; Robert Wainer; Philippe de Mazancourt; Jacqueline Selva; François Vialard
Journal:  J Assist Reprod Genet       Date:  2012-10-27       Impact factor: 3.412

3.  Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation.

Authors:  Travis J O'Brien; Mariah M Kalmin; Arthur F Harralson; Adam M Clark; Ian Gindoff; Samuel J Simmens; David Frankfurter; Paul Gindoff
Journal:  Reprod Biol Endocrinol       Date:  2013-07-25       Impact factor: 5.211

4.  Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study.

Authors:  Kazem Nouri; Peter Haslinger; Ladislaus Szabo; Michael Sator; Martin Schreiber; Christian Schneeberger; Detlef Pietrowski
Journal:  J Ovarian Res       Date:  2014-05-13       Impact factor: 4.234

5.  Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome.

Authors:  Nasrin Ghasemi; Razieh Dehghani Firouzabadi; Shahnaz Ahmadi
Journal:  Int J Reprod Biomed (Yazd)       Date:  2017-02

6.  Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation.

Authors:  Hans I Hanevik; Hilde T Hilmarsen; Camilla F Skjelbred; Tom Tanbo; Jarl A Kahn
Journal:  Reprod Biol Endocrinol       Date:  2014-03-13       Impact factor: 5.211

7.  Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome.

Authors:  Travis J O'Brien; Arthur F Harralson; Tuyen Tran; Ian Gindoff; Funda E Orkunoglu-Suer; David Frankfurter; Paul Gindoff
Journal:  Reprod Biol Endocrinol       Date:  2014-05-09       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.